About Immatics
Immatics is a company based in Tubingen (Germany) founded in 2000. Immatics has raised $236.4 million across 9 funding rounds from investors including 3i Group, European Union and KfW. The company has 423 employees as of December 31, 2024. Immatics offers products and services including Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT. Immatics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Tubingen, Germany
- Employees 423 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immatics N.V.
-
Annual Revenue
$168.57 M (USD)188.75as on Dec 31, 2024
-
Net Profit
$16.46 M (USD)0as on Dec 31, 2024
-
EBITDA
-$28.63 M (USD)72.31as on Dec 31, 2024
-
Total Equity Funding
$236.4 M (USD)
in 9 rounds
-
Latest Funding Round
$35 M (USD), Post-IPO
Jul 24, 2023
-
Investors
3i Group
& 15 more
-
Employee Count
423
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Immatics
Immatics is a publicly listed company on the NASDAQ with ticker symbol IMTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Immatics
Immatics offers a comprehensive portfolio of products and services, including Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT.
T cell-based treatments targeting solid tumors in clinical trials.
Bispecific antibodies for enhancing T cell responses against cancer.
Innovative cell therapies for improved cancer treatment efficacy.
People of Immatics
Unlock access to complete
Unlock access to complete
Funding Insights of Immatics
Immatics has successfully raised a total of $236.4M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immatics
Immatics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include 3i Group, European Union and KfW.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity investments are managed.
|
Locked | Locked | Locked | |
|
Investments are made in early-stage healthcare startups.
|
Locked | Locked | Locked | |
|
Investments are made in life and health sciences companies.
|
Locked | Locked | Locked |
Investor details for Immatics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immatics
Investment portfolio details for Immatics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immatics
Detailed financials for Immatics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immatics Comparisons
Peer comparison for Immatics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immatics
Immatics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Immatics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immatics
Complete news archive for Immatics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immatics
Immatics was founded in 2000 and raised its 1st funding round 4 years after it was founded.
Immatics is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
Immatics is a funded company, having raised a total of $236.4M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Immatics is 423.
Annual revenue of Immatics is $168.57M as on Dec 31, 2024.
Founded in 2000 and based in Tubingen, Germany, the company operates in the biotechnology sector, focusing on cancer immunotherapies. A proprietary platform called XPRESIDENT is utilized to identify and validate cancer-specific antigens. Adoptive cell therapies and bispecific T-cell receptors are subsequently developed for cancer treatment. The IMA101 product is generated through the ACTolog approach, employing T-cells from peripheral blood with targeted selectivity.
Immatics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Immatics offers Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT.
Yes, Immatics is publicly traded on NASDAQ under the ticker symbol IMTX.
Immatics has 16 investors. Key investors include 3i Group, European Union, KfW, Bristol-Myers Squibb, and DH Capital.
The ticker symbol of Immatics is IMTX on NASDAQ.